As of the date of this review, 37 monoclonal antibody products are approved for use in cancer treatments in the United Kingdom. Currently, the antibody therapeutics market is dominated by monoclonal immunoglobulins (IgGs). New types of recombinant antibody therapeutics developed more recently include bispecific recombinant antibodies and other recombinantly produced functional proteins. This review focuses on the approved therapeutic antibodies used in cancer treatment in the UK today and describes their antigen targets and molecular mechanisms involved…
Therapeutic antibodies are becoming of greater importance in the treatment of malignancies, especially those that show resistance to more traditional therapy such as chemotherapy agents and radiotherapy. More and more, these antibodies are showing that they can increase overall survival, disease-free survival and delay disease progression in several malignancies. More specifically, these antibodies also provide treatment options in non-resectable cancers and aid in delaying disease progression. Alongside this, many new therapeutic antibodies started being used as first-line treatment in many haematological malignancies. As we continue to understand the complex pathways that lead to carcinogenesis and the anti-immune properties that many cancers possess, this will continue to lead to more targeted therapeutic antibody treatments and potentially improved outcomes for patients with cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9739895/
Speak Your Mind